HC Wainwright & Co. Maintains Buy Rating for TG Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has reaffirmed its Buy rating on TG Therapeutics (NASDAQ:TGTX) and increased its price target from $41.00 to $45.00. TG Therapeutics' stock is currently trading at $17.77, and the new price target suggests a potential upside of 153.24%. The company, which focuses on B-cell disease treatments, has recently received FDA approval for BRIUMVI for RMS and is developing other treatments in Phase 1 trials.

January 11, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on TG Therapeutics and raises the price target to $45, indicating a significant upside from the current price of $17.77.
The reaffirmation of a Buy rating and an increased price target by a reputable analyst firm like HC Wainwright & Co. can have a positive impact on investor sentiment and potentially drive the stock price up in the short term. The substantial potential upside of 153.24% highlighted by the new price target may attract investor interest and buying activity. However, as analyst ratings are subject to human error and the actual performance of the company's products in development is uncertain, the confidence level is not at the maximum.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100